EX-99.1

Safe Harbor Statement

Certain statements contained in this presentation are forward-looking statements and are based on future

expectations, plans and prospects for the business and operations of InfuSystem Holdings, Inc. (“InfuSystem”

or “the Company”) that involve a number of risks and uncertainties. In connection with the “safe harbor”

provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors

that could cause actual results to materially differ from those indicated by these forward-looking statements.

Those factors, risks and uncertainties include, but are not limited to: potential changes in overall healthcare

reimbursement, including CMS competitive bidding; sequestration; concentration of customers; increased

focus on early detection of cancer; competitive treatments; dependency on Medicare Supplier Number;

availability of chemotherapy drugs; global financial conditions; changes and enforcement of state and federal

laws; dependency on suppliers; risks associated with acquisitions and joint ventures, including integration

risks; US Healthcare Reform; relationships with healthcare professionals and organizations; technological

changes related to infusion therapy; [dependency on websites and intellectual property; dependency on key

personnel; dependency on banking relationships; risks associated with our common stock, as well as any

litigation to which the Company may be subject from time to time; and other risk factors as discussed in the

Company’s annual report on Form 10-K for the year ended December 31, 2013 and in subsequent filings

made by the Company from time to time with the Securities and Exchange Commission (the “SEC”), which can

be obtained via the SEC’s Edgar website or by contacting the Company or the SEC. Forward-looking

statements in this presentation are made as of December 1, 2014, and, unless required by law, the Company

disclaims any duty to supplement, update or revise such statements, whether as a result of subsequent

developments, changed expectations or otherwise. The Company regularly posts important information to

the investors section of its website.

Summary

InfuSystem is a growing healthcare company that

provides infusion pumps and related products and

services for patients in the home, in oncology clinics,

ambulatory surgery centers, and other sites of care

from five locations serving all 50 States and

Canada.

We deliver improved patient satisfaction

and outcomes with world-class quality, both in and

out of the home environment.

The company's

market share and profitable growth is predicated on

expansion into new therapies, increased use of

electronic connectivity, development of new

products and services, and strategic geographic

expansion.

Confidential Information of InfuSystem Holdings, Inc.

InfuSystem -

“Infusion Made Easy”

9 mos YTD September 30, 2014

(1)

Revenues $50.2M (Up 11%)

AEBITDA $11.5M (Up 2%)

Market Cap $64.0M @ $2.87 (as of

11/20/14)

Company Overview

Provides infusion pumps and related

products and services for patients in:

The Patient’s Home

Oncology Clinics

Ambulatory Surgery Centers

And Other Sites of Care

Serves all 50 States & Canada

from 5 locations

Improves outcomes and delivers high

patient satisfaction with world-class ISO

and CHAP accredited quality

Profitable growth is predicated on:

Growth of oncology and orthopedic

surgery

Increased electronic connectivity

New products and services

Strategic geographic expansion

(1) Free Cash Flow = Adjusted EBITDA less CapEx and Purchases of

Medical Equipment

“The right pump, the right place, and the right time.

Working and patient ready.”

Financial Overview

Adjusted EBITDA (1)

Revenues

Free Cash Flow (1)

Basic EPS

(1) Free Cash Flow = Adjusted EBITDA less CapEx and Net Purchases of Medical Equipment

$38,964

$47,229

$54,637

$58,828

$62,280

$67,404

$30m

$40m

$50m

$60m

$70m

FY2009

FY2010

FY2011

FY2012

FY2013

LTM 3Q14

Revenues

Growing

$10,256

$13,126

$15,962

AEBITDA

Growing

$16,153

$6m

$10m

$14m

$18m

FY2011

FY2012

FY2013

LTM 3Q14

(1) Per 8K filed 3/28/13 for yrs 2011 and 2012

$5,754

$10,568

$11,839

$12,604

$4m

$8m

$12m

$16m

FY2011

FY2012

FY2013

LTM 3Q14

FCF

Growing

(4)

(5)

(4)

(3)

(2)

(1)

FY 2012

FY 2013

FY 2014

EPS Profitable &

Growing

Positioned For Growth

Market Trends

•

InfuSystem is uniquely

positioned to take efficient

advantage of growing

market trends in…

•

Oncology

•

Orthopedic surgery

•

Growth of home infusion

Leadership

•

Experienced Medical

Industry Executives

•

Focused on improving

patient satisfaction and

outcomes

•

Supported by World Class -

ISO and CHAPS Accredited -

facilities and motivated

employee

Strategy

•

Increased use of electronic

connectivity

•

Expanding geographic

footprint

•

Expanding into new

therapies, products and

services

InfuSystem Niche –

Extension of Clinic to Home

25-year old business model in

DME billing

At home, at work, at play, all

while receiving the drug

High satisfaction scores

24/7 on-call oncology nurses

Proven outcomes with

continuous home infusion

Oncology, Post Surgical Pain,

Special Disease States

Bills patient insurance

250+ Commercial and

Government Payor

Contracts

Commercial Payors

reimburse more

therapies than CMS

Awarded contracts in

all 9

MSAs (1 of 3

National Vendors)

Average cuts of ~21%

for our category, per

CMS ($250,000 per yr)

Ambulatory Home Infusion

TPP Payor Contracts

Rentals, Sales & Service to Providers

Pump Experts

Direct sales, rental, and

lease of device and

supplies in US and

Canada

Pump Broker Expertise –

ability to acquire and

dispose of CAP EX in cost

effective way

Asset management,

rental and lease

Annual Pump

Recertification

Preventative

Maintenance

Warranty

World-Class ISO Certified

service facilities

Regional Distribution

West, South, East &

Canada

28+ Certified Technicians

Pump Rentals, Sales and

Asset Management

Preventative Maint.

Repair

Compelling Value Proposition

In-House Service & Repairs

Convenience & Flexibility

Pre-Owned Equipment Expertise

One-Stop Shopping Solution

Convenience and flexibility of rentals and

financing minimize customer capital outlays

Rental and financing eliminates the need for

in-house maintenance/service

Option to own, rent or finance –

designed to fit

customers’

operating and financial parameters

Shorter and longer-term financing options

One-stop shopping solution for ambulatory large

volume pump and other movable medical devices

Sales

Rentals

Supplies

Service

Financing

World-class biomedical repair and

service for pumps, defibrillators and

most other general medical

equipment

Allows InfuSystem to purchase, clean,

repair and certify any used medical

equipment the Company buys for

subsequent sale, rental or financing to

customers

Complementary core competencies allow InfuSystem to offer superior selection, flexibility, pricing and services

“ONE-STOP SHOP”

SERVICE &

REPAIRS

CONVENIENCE &

FLEXIBILITY

PRE-OWNED

EQUIPMENT

EXPERTISE

Unique ability to source and deploy pre-

owned movable medical equipment

Consistent, fair and knowledgeable

market maker for pre-owned pump

disposals

Market knowledge results in attractive

equipment acquisition costs

Payor & Customer Mix

Leading Cancer Institution Customers

Revenue by Payor (FY2013)

High diversification of providers and payors

No single healthcare provider represents more than 7% of Third-Party Payor revenues

Strong payor mix among Medicare, other commercial insurers, Blue Cross/Blue Shield, and Medicaid

Approximately 6% of revenues received directly from patients through co-pays or otherwise

Broad coverage further diversifies revenue streams

InfuSystem has strong relationships with the largest third-party payors and the leading cancer institutions

9 of 10 of the Top

Ten Cancer

Treatment Centers

CMS: Centers for Medicare and Medicaid Services

Medicare and

Medicaid

38%

BCBS

17%

Patient

Commercial

39%

Infusion pumps

Enteral pumps

Direct Payor Business Model

Service & Repair

Products

InfuSystem sells, rents and finances a wide variety of new

and used large volume and ambulatory pumps

InfuSystem services and repairs both its own fleet of

pumps and many types of other movable medical

equipment

Syringe pumps

Ambulatory pumps

Large volume pumps

Ambulatory pumps

Fluid collection

Medical equipment

InfuSystem’s Direct Payor business is focused primarily on the sale, rental, financing and accompanying service of

movable

medical

equipment

hospitals

and

alternate

care

sites

who

pay

InfuSystem

directly

–

third-party

reimbursement

Founded in 1998 and headquartered in Olathe, KS with distribution/service centers in Santa Fe Springs, CA and

Mississauga, Ontario

InfuSystem services –

ISO 9001 -

and repairs movable medical equipment

Leading provider to alternate site healthcare facilities and hospitals in the United States and Canada

Home infusion providers, long-term care, physician clinics, research facilities, etc.

Transacts

directly

with

healthcare

providers

–

third-party

reimbursement

revenue

InfuSystem offers new pumps from top brands

Broker-dealer trading desk

In addition, over 70 models and versions of pre-owned pumps

are offered

Pre-owned pumps are re-built and certified by in-house

biomedical technicians to be patient ready

Warranty offered on pre-owned pumps

A variety of financing options to fit customers’

operating,

budgeting and financing parameters

Nationwide, industry-leading ISO 9001 service programs

Launching branch service center in Houston

Direct Payor Offerings

Pre-Owned & New Pumps from Top Manufacturers

Full Spectrum of Ownership Options for Customers

Sales

Rental

Asset Management

Renting new or pre-owned equipment

Rent pumps by the day, week or month to

match swings in patient count

Free shipping on all rentals

Industry leader in sales of pre-owned

equipment, creating significant savings

Competitive pricing on new equipment

Option to sell back pre-owned pumps

Leasing plans offered

ISO 9001 Service offered

Service plans offered

Local service expansion

2 existing; 1 planned

Coordinate with TPP

Loaner pumps available

Leading Provider of New and Pre-Owned Pumps

Medical Equipment Service & Repair

In addition to supporting and repairing

InfuSystem’s in-house fleet, the Company certifies,

recalibrates, repairs and services a variety of

infusion pumps

Pumps require scheduled maintenance and

calibration in accordance with manufacturer’s

specifications and regulatory guidelines

Service and repair capabilities on high demand

services reaching end of life that are no longer

supported by manufacturers

ISO certification and an established quality system

strengthens relationships with major customers

Provides InfuSystem an opportunity to establish a

business relationship with customers that acquired

pumps through other sources

Continuing and increased need for compliance

with current as well as anticipated regulations

28 highly qualified service technicians

5 major manufacturer relationships:

3 service centers, located in California,

Toronto and Kansas

Competitive Bidding Overview

InfuSystem was not involved in Round 1 nor

Round 2 of Competitive Bidding

CMS announced a Recompete of Round 1

competitive bidding on April 17th

External infusion pumps/supplies added as a

new product category

A supplier must bid on all items within the

product category to have its RFP considered

Recompete covers 9 Metropolitan Statistical

Areas (MSAs)

Competitive Bidding Overview

InfuSystem’s Response to Competitive Bidding

InfuSystem has engaged consultants and industry

professionals to discuss directly with CMS, advise

on positioning the Company for potential

regulatory changes, and facilitate potential

strategic partnership opportunities

InfuSystem was awarded contracts in all 9 MSAs

with average cuts of ~21% for our category per

CMS. 1 of 3 National Vendors to receive

contracts in all 9 markets.

“Competitive environment will vary in accordance

with the level of cuts by CMS”

CMS Competitive Bidding “Target”

Timetable

CMS will institute some form of competitive

bidding nationwide by January 2016.

CMS began the pre-

bidding supplier

awareness program

CMS announced bidding

schedule, start bidder

education and begin a

bidder registration period

Bid window

opens

Current Round 1 bid

contracts expire

CMS announces Round

1 Recompete bid

results –

INFU impact

$250K annually

Bid window

closes

Implementation of

Round 1 bid contracts

and prices

Detailed Historical P&L

(000's)

12/31/09

12/31/10

12/31/11

12/31/12

12/31/13

9M 2013

9M 2014

Net revenues:

Rentals

46,795

53,471

55,962

41,556

44,150

Product sales

7,842

5,357

6,318

3,547

6,077

Net revenues:

38,964

47,229

54,637

58,828

62,280

45,103

50,227

Cost of Revenues:

Product, service and supply costs

6,200

7,730

9,128

9,165

11,274

8,174

9,024

Pump depreciation and loss on disposal

4,127

5,954

10,154

6,752

7,327

4,836

5,474

Gross Profit

28,637

33,545

35,355

42,911

43,679

32,093

35,729

Provision for doubtful accounts

4,006

4,515

4,099

5,251

6,534

4,782

4,811

Amortization of intangibles

1,827

2,259

2,662

2,734

2,618

1,972

1,876

Asset impairment charges

67,592

Selling and marketing

5,258

7,087

9,371

9,864

9,658

7,281

7,762

General and administrative

12,218

20,622

17,987

23,062

18,973

14,622

14,723

Operating income profit/(loss)

5,328

(938)

(66,356)

2,000

5,896

3,436

6,557

Total other gain/(loss)

(3,577)

(2,285)

(2,221)

(4,152)

(3,196)

(2,307)

(2,329)

Profit/(loss) before income taxes

1,751

(3,223)

(68,577)

(2,152)

2,700

1,129

4,228

Income tax benefit/(expense)

(977)

1,371

23,134

663

(1,031)

(324)

(1,907)

Net income/(loss)

774

(1,852)

(45,443)

(1,489)

1,669

805

2,321

EBITDA

11,199

7,745

(57,336)

9,590

14,230

9,747

11,054

EBITDA (ex. Impairment charges)

11,199

7,745

10,256

9,590

14,230

9,747

11,054

Adjusted EBITDA

N/A

10,256

13,126

15,954

11,271

11,471

Detailed Historical BS

(000's)

12/31/09

12/31/10

12/31/11

12/31/12

12/31/13

6/30/14

9/30/14

ASSETS

Current Assets:

Cash and cash equivalents

7,750

5,014

799

2,326

1,138

1,041

1,902

Accounts receivable - total, net of allowance

5,517

6,679

7,448

8,511

10,697

10,768

11,505

Inventory

925

1,699

1,309

1,339

1,234

1,485

1,589

Prepaid expenses and other current assets

395

750

934

684

518

712

621

Deferred income taxes

125

1,147

682

1,971

2,296

Total Current Assets

14,712

15,289

11,172

14,831

15,883

16,302

17,913

Total PP&E and Medical Equipment

13,499

16,672

17,672

16,564

18,974

20,017

22,397

Deferred debt issuance costs, net

781

658

421

2,362

1,817

1,505

1,349

Total Goodwill and Intangible assets, net

85,491

97,344

28,221

25,541

24,182

24,287

24,461

Deferred income taxes

18,187

17,806

16,300

15,376

14,696

Other assets

207

401

590

419

217

248

208

Total Assets

114,690

130,364

76,263

77,523

77,373

77,735

81,024

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:

Accounts payable - total

1,306

2,016

4,063

2,144

4,736

4,101

4,570

Accrued expenses and other

1,573

4,631

2,235

4,098

3,187

2,573

3,303

Derivative liabilities

2,670

183

258

Current portion of long-term debt

5,501

5,551

6,576

3,953

5,118

3,871

4,238

Total Current Liabilities

11,050

12,381

13,132

10,195

13,041

10,545

12,111

Long-term debt, net of current portion

18,640

26,646

22,551

27,315

21,609

22,829

23,631

Deferred income taxes

3,314

5,788

Other liabilities

221

406

415

Total Liabilities

33,225

45,221

36,098

37,510

34,650

33,374

35,742

Total Stockholders' Equity

81,465

85,143

40,165

40,013

42,723

44,361

45,282

Total Liabilities and Equity

114,690

130,364

76,263

77,523

77,373

77,735

81,024

Total Debt

24,141

32,197

29,127

31,268

26,727

26,700

27,869

Net Debt

16,391

27,183

28,328

28,942

25,589

25,659

25,967

Comparison to Other Infusion Companies

Stock Comparison

As of 11/20/14

BioScrip

Infu

Stock Price

$ 5.99

2.85

52 Week hi

$ 9.05

4.50

52 Week lo

$ 5.44

1.70

Average Volume

1,000,850

174,194

In $ millions

Market Cap

$411.1m

$63.3m

P/E Ratio

(trailing)

N/A

20.29x

P/E Ratio

(forward)

75.12x

8.82x

Enterprise Value

$821.4m

$89.5m

Revenues (ttm)

$1,030m

$60.8m

Net Income (ttm)

$(93.6)m

$3.18m

EBITDA (ttm)

$(3.5)m

$16.7m

EBITDA Margin (% of rev)

N/A

27.4%

EV / EBITDA

N/A

5.4x

EBITDA Anlayst (FY2014)

$55.0m

17.4

EV / EBITDA

14.9x

5.1x

Stock Comparison

Source: Yahoo Finance

•

INFU has no direct small DME

niche public company comp.

•

One often mentioned is

BioScrip Inc. (BIOS), but like

most other potential comps it is

broadly diversified beyond the

infusion sector.